All In Biotech

Drug Trial Radar · NCT00262067

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,237 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,237

Actual

Start

Dec 2005

Primary completion

Jul 2008

Study completion Dec 2013

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 6, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • BevacizumabDrug

    Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.

  • PlaceboDrug

    Placebo consisted of the vehicle for bevacizumab without the antibody.

  • ChemotherapyDrug

    The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle 1. Docetaxel 75-100 mg/m\^2 IV 2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle 1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV 2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV 3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV 4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)Time frame: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)

Locations

92 sites in 22 countries. Site status is shown where the registry gives one.

  • Site not named

    Fullerton, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Iowa City, Iowa

  • Site not named

    Sioux City, Iowa

  • Site not named

    Wichita, Kansas

  • Site not named

    Geelong, Australia

  • Site not named

    Malvern, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Southport, Australia

  • Site not named

    Wahroonga, Australia

  • Site not named

    Waratah, Australia

  • Site not named

    Wollongong, Australia

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Salvador, Brazil

  • Site not named

    Santo André, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Winnipeg, Manitoba, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Reims, France

  • Site not named

    Saint-Herblain, France

  • Site not named

    Strasbourg, France

  • Site not named

    Athens, Greece

  • Site not named

    Chania, Greece

  • Site not named

    Heraklion, Greece

  • Site not named

    Pátrai, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Guatemala City, Guatemala

  • Site not named

    Acapulco, Mexico

  • Site not named

    Aguascalientes, Mexico

  • Site not named

    Mérida, Mexico

  • Site not named

    Monterrey, Mexico

  • Site not named

    Monterrey, Mexico

  • Site not named

    Amstelveen, Netherlands

  • Site not named

    Apeldoorn, Netherlands

  • Site not named

    Delft, Netherlands

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.